

Translation

Notice: This document is a translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.



April, 10, 2026

To Whom It May Concern:

Company Name: Daito Pharmaceutical Co., Ltd.  
Representative: Hiroshi Matsumori, President and CEO  
(Securities Code: 4577, Prime Market of Tokyo Stock Exchange)  
Inquiries: Kenji Otsuga, Executive Officer, CFO  
(Telephone Number: +81-76-421-5665)

**Notice Regarding Revision of Earnings Forecasts**

Daito Pharmaceutical Co., Ltd. (the “Company”) hereby announces that on the basis of recent operational performance, etc., the Company has revised the full-year group earnings forecast for the fiscal year ending May 31, 2026 (June 1, 2025 to May 31, 2026), which was released on July 11, 2025, as detailed below.

1. Revised Figures for the Full-year Group Earnings Forecast for the Fiscal Year Ending May 31, 2026 (June 1, 2025 to May 31, 2026)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Consolidated earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previously announced forecasts (A)	52,500	3,000	3,000	2,300	76.70
Revised forecasts (B)	51,000	3,300	3,500	2,500	84.38
Change (B-A)	(1,500)	300	500	200	—
Change (%)	(2.9)	10.0	16.7	8.7	—
(Reference) Actual consolidated results for the previous fiscal year (Fiscal year ended May 31, 2025)	50,643	2,619	2,705	1,908	62.74

(Note) Daito Pharmaceutical Co., Ltd. implemented a 2-for-1 stock split of its common stock effective June 1, 2025. Consolidated net income per share has been calculated assuming that the stock split was conducted at the beginning of the previous consolidated fiscal year.

2. Reason for Revision

Net sales are expected to be lower than the initial forecast due to factors such as inventory adjustments by customers and changes in sales strategies in the Chinese market.

On the other hand, in terms of profit, full-year operating profit, ordinary profit, and net income

attributable to owners of parent are all expected to exceed the initial forecasts. This is primarily due to an increase in the ratio of FDF products within the sales mix, lower-than-expected depreciation expenses following a change in accounting policies, and lower-than-expected R&D costs resulting from a review of development plans and the rescheduling of BE tests. Accordingly, Daito Pharmaceutical Co., Ltd. has decided to revise its earnings forecast as stated above.

Note: The earnings forecast above is based on information available for the Company as of the announcement day and may differ from the actual results of the Company in the future.

End